AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-305-671-0200**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member AvMed #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code:** _____

Weight: _____ **Date:** _____

Maximum Approved Dose:

- **Children ≥ 2 years to < 6 years weighing < 14 kg:** Oral: 1 packet (containing elexacaftor 80 mg/tezacaftor 40 mg/ivacaftor 60 mg) in the morning and 1 packet (containing ivacaftor 59.5 mg) in the evening
- **Children ≥ 2 years to < 6 years weighing > 14 kg:** Oral: 1 packet (containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning and 1 packet (containing ivacaftor 75 mg) in the evening
- **Children ≥ 6 years to < 12 years weighing < 30 kg:** Oral: 2 tablets (each containing elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg) in the morning and ivacaftor 75 mg in the evening, approximately 12 hours apart
- **Children ≥ 6 years to < 12 years weighing ≥ 30 kg:** Oral: 2 tablets (each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning and ivacaftor 150 mg in the evening, approximately 12 hours apart
- **Children ≥ 12 years, Adolescents and Adults:** Oral: 2 tablets (each containing elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg) in the morning and one ivacaftor 150 mg tablet in the evening, approximately 12 hours apart

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 6 months

- ❑ Member is **2 years of age or older** with a diagnosis of Cystic Fibrosis
- ❑ Member has **at least one** of the F508 del mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene as confirmed by an FDA-cleared test that is responsive to elexacaftor/tezacaftor/ivacaftor **(Test results must be attached)**
- ❑ Prescribing physician is a pulmonologist or has consulted with a pulmonologist who specializes in the treatment of Cystic Fibrosis
- ❑ Baseline FEV1 within the last 30 days must be submitted, unless the member is unable to perform a pulmonary function test **(Test results must be attached)**
- ❑ Provider attests that baseline ophthalmic examination to monitor lens opacities/cataracts has been completed for pediatric members
- ❑ Baseline liver function tests have been completed prior to initiating therapy and will be completed annually **(Labs must be attached)**
- ❑ Member does **NOT** have severe hepatic impairment (Child-Pugh Class C)
- ❑ Number of pulmonary exacerbations or hospitalizations in the preceding 6 months must be noted: _____
- ❑ Baseline body mass index must be noted: _____
- ❑ Member will **NOT** be taking Trikafta® in combination with any other CFTR modulator therapy (i.e., Symdeko®, Orkambi®, Kalydeco®) **NOTE**: Concurrent therapy with these agents will **NOT** be approved
- ❑ Member will avoid concomitant use of strong CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort) and strong or moderate CYP3A inhibitors (e.g., fluconazole, itraconazole)

Reauthorization: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member continues to meet initial criteria
- ❑ Member has demonstrated disease response as indicated by **one or more** of the following **(must submit current labs and chart notes)**:
  - ❑ Decreased pulmonary exacerbations or hospitalizations compared to pretreatment baseline
  - ❑ Stabilization of lung function as measured by FEV1 within the last year compared to baseline
  - ❑ Improvement in quality of life, weight gain, or growth
- ❑ Member has **NOT** received a lung transplant
- ❑ Member has experienced an absence of unacceptable toxicity from therapy (i.e. elevated transaminases (ALT or AST), development of cataracts or lens opacities)

(Continued on next page)

Date of initiation of Trikafta® therapy: _____	Reauthorization Date: _____
Baseline FEV1 **(last FEV1 prior to starting Trikafta®)**: _____	Current FEV1 **(FEV1 AFTER last dose of Trikafta®)**: _____
Baseline Weight: _____	Current weight: _____
Baseline BMI: _____	Current BMI: _____
Number of hospitalizations since last approval of Trikafta® must be noted _____	

Medication being provided by a Specialty Pharmacy – Proprium Rx

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****